Efficacy of Biomarkers and CEUS Versus CTA in AAA Follow-up Post-EVAR

Launched by INSTITUTO DE INVESTIGACION SANITARIA LA FE · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how effective a new method using contrast-enhanced ultrasound (CEUS) and certain blood tests (biomarkers) is for monitoring patients with abdominal aortic aneurysm (AAA) after they have undergone a procedure called Endovascular Aneurysm Repair (EVAR). Currently, the standard way to check on these patients is through a test called computed tomography angiography (CTA), which involves radiation and a special dye that can be harmful to the kidneys. The researchers want to see if using CEUS and biomarkers can provide a safer and just as effective way to monitor these patients, helping to reduce the risks associated with CTA.

To participate in this trial, you need to be between 65 and 74 years old, have an AAA that is being treated with EVAR, and be willing to undergo both CTA and CEUS tests along with blood tests for biomarkers. If you qualify, you can expect to have CEUS done at different times after your EVAR procedure, and your results will be compared to those from the CTA to see how well they match. The goal is to find a follow-up method that minimizes exposure to radiation and harmful contrast agents while still effectively monitoring your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with AAA under follow-up who are going to be treated with EVAR.
• • signed informed consent to perform CTA, CEUS and for the determination of biomarkers.
• Exclusion Criteria:
• • patients with inflammatory abdominal aortic aneurysms or ruptured aneurysm.